RAD BioMed News
10 articles
growth-positive
A chance encounter at university led Dr. Eyal Orion to the Zisapel brothers’ RAD Biomed incubator, setting him on a path to found five medical device companies, including one sold for $100 million. This month, he achieved a second exit with the $497 million sale of Vectorious, developer of a heart failure–detecting sensor.
Vectorious, a medical device company founded by Dr. Eyal Orion, was acquired by Edwards Lifesciences for $497 million. The company developed a heart failure-detecting sensor, V-LAP, which is implanted in the heart to monitor pressure and provide early warnings of fluid congestion. This acquisition marks a significant milestone for Vectorious, which has been preparing for a pivotal clinical trial to gain FDA approval. The partnership with Edwards, which began with an investment in 2020, has grown into a full acquisition, allowing Vectorious to leverage Edwards expertise in navigating regulatory and medical ecosystems. The acquisition highlights the potential of Israeli innovation in the medical device sector.
Acquired-by
growth-positive
Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets
Everads Therapy has announced a milestone achievement within its collaboration with a global pharmaceutical company. The pharmaceutical company has been granted exclusivity to utilize Everads suprachoroidal delivery technology for the development of specific ocular targets, in exchange for a milestone payment. Everads retains the right to continue using and licensing its technologies for other therapies. The company is optimistic that the collaboration will lead to a commercial license. Everads Therapy is a life sciences company focused on developing a revolutionary delivery system for suprachoroidal delivery of injectable therapies.
Partners
growth-positive
Belkin Laser announces $12.2 million raised in series B funding
Israeli medtech startup Belkin Laser has completed a $12.2 million series B financing round led by Rimonci Capital and Santen Ventures Inc. The company, which develops a one-second glaucoma treatment, has raised a total of $21.3 million in funding. Belkin Laser plans to use the capital to continue its clinical trials and launch new trials in Asia. The product is expected to enter the market in two years. The financing round included participation from BioLight Life Sciences, C-Mer Eye Care Holdings, and CR-CP Life Science Fund. Belkin Laser had previously raised $6.6 million from grants and a $2.5 million investment in a series A round led by ZIG Ventures.
Investment
growth-positive
VasQ™ External Support Awarded Breakthrough Device Designation by the FDA
The FDA has designated Laminate Medicals VasQ External Support for the creation of arteriovenous fistulas (AVF) in hemodialysis patients as a Breakthrough Device. This designation is expected to provide additional reimbursement for new technologies. The VasQ External Support has consistently demonstrated improvement over the standard of care for creating functional AVFs for hemodialysis treatment. The device is currently in a U.S. IDE pivotal clinical study and is expected to receive market clearance in the U.S. Laminate Medical Technologies is dedicated to making better fistulas for hemodialysis patients.
Customers
growth-positive
Zsquare Named A Silver Winner of the 2020 Edison Awards
Zsquare has been named a silver winner in the Medical/Dental category at the 2020 Edison Awards. Zsquare offers ultra-thin, flexible, high-resolution single-use endoscopes that eliminate the risk of infections caused by contaminated, reused endoscopes. The award recognizes Zsquare as a game-changing innovation in the medical field. The company aims to transform the way endoscopes are used worldwide and address the problem of cross-contamination. Zsquare is a privately-held medical device company based in Israel.
CustomersPartners
Vectorious' V-LAP arrives in Israel: Live interview with Dr. Leor Perl
growth-positive
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies
Everads Therapy has signed an option agreement with a large global pharmaceutical company to evaluate its suprachoroidal delivery system. This is Everads first commercial agreement and supports the potential of its technology to improve retinal disease treatment options. The pharma company has an exclusive option to enter into a license agreement with Everads and will pay an up-front fee, milestone payments, and ongoing royalties. The agreement builds confidence in Everads suprachoroidal drug delivery approach. Everads delivery system overcomes technical challenges in effective suprachoroidal injection and may provide superior outcomes compared to current injection methods. The company aims to improve the treatment of macular disease. Everads Therapy is a life sciences company operating within the RAD Biomed incubator in Tel Aviv, Israel.
Partners
growth-positive
Enrollment of the VasQ™ External Support US Pivotal Study Now Complete
Laminate Medical Technologies has completed enrollment into the VasQ External Support US Pivotal Study, which aims to address the high failure rates of arteriovenous fistulas (AVFs) used for hemodialysis. The study enrolled 144 male and female patients across 17 sites in the U.S. The VasQ device, a nitinol external support, is designed to optimize the transition of arterial flow to the vein and reinforce the vessel wall to prevent AVF failure. The results of the study are expected to support the benefits of VasQ and potentially become a new standard of care for AVF creation. Laminate Medical Technologies plans to build upon the success of VasQ with additional devices in development.
Customers
growth-positive
Perflow Medical Receives CE Mark Approval of Novel Cascade™ Agile
Perflow Medical has received CE Mark approval for the Cascade Agile Non-Occlusive Remodeling Net, expanding their product family for neurovascular treatment. The Cascade Agile provides optimized control for coil embolization of intracranial aneurysms. Perflow Medical also published an article highlighting clinical experience with the Cascade Net for the treatment of ruptured intercranial aneurysms. The companys focus on providing physicians with more control and better information during complex procedures has been well received. They are planning to publish their clinical experience with other products and expand their commercial presence. Perflow Medicals products are commercially available in Europe but not approved for clinical use in the United States.
CustomersPartners
growth-positive
VGS Completes Enrollment of VEST U.S. Pivotal Trial for the Evaluation of Its Venous External Support Technology for Coronary Bypass Surgery
Vascular Graft Solutions Ltd. (VGS) has completed patient enrollment in its US Investigational Device Exemption (IDE) randomized, controlled pivotal study. The study evaluated the efficacy of the VEST external support for saphenous vein grafts in coronary artery bypass (CABG) surgery. The study enrolled 224 patients at 17 clinical sites in the US and Canada. VGS is a privately held company located in Tel Aviv, Israel, that develops novel solutions in the field of cardiovascular surgery. The VEST device has undergone several randomized trials in leading heart centers in Europe and has been successfully implanted in approximately 3,000 patients. It is currently commercialized in several EU countries, Mexico, and South Africa.
Customers
